J&J Shares Up 17% YTD as Bayer Lawsuit and Gilead $7.8B Deal Threaten Growth
J&J shares have rallied 17% YTD led by high-growth oncology sales, a MedTech rebound and a surprise earnings beat that outpaced new tariff pressures. The company now faces a lawsuit from Bayer over prostate cancer drug marketing and mounting competition from Gilead’s $7.8 billion deal for a rival therapy.
1. Stock Performance Boosted by Oncology, MedTech, Earnings
Johnson & Johnson’s share price has climbed 17% year-to-date as robust sales from its oncology portfolio, a rebound in its MedTech division and a surprise fourth-quarter earnings beat that defied new tariff-related headwinds bolstered investor confidence.
2. Legal Risk from Bayer Lawsuit
Bayer filed suit against Johnson & Johnson alleging breach of their co-marketing agreement for a prostate cancer drug, claiming J&J overstated efficacy in promotional materials and seeking unspecified damages that could pressure revenue from the blockbuster therapy.
3. Rising Competition from Gilead’s $7.8B Deal
Gilead Sciences struck a $7.8 billion agreement to acquire rights to a promising oncology candidate designed to compete directly with J&J’s prostate cancer treatment, heightening competitive pressures on future sales and market share.